Abstract Submission

This category invites late-breaking research on the role of medical imaging in cancer screening. The focus should be on strategies that improve risk prediction/stratification and early cancer detection with possible integration of clinical, genomic, molecular, or related fluidic biomarkers. Examples of patient care impacts can include better identification of at-risk individuals, reduction in overdiagnosis and overtreatment and personalized screening intervals.

This category invites late-breaking research on the use of medical imaging to detect, characterize, monitor, or risk-stratify chronic and metabolic diseases particularly in their early stages. This includes cardiovascular disease, chronic kidney disease, diabetes, obesity, liver disease, and related multisystem conditions. Submissions may include opportunistic screening, quantitative imaging biomarkers, body composition and organ-specific measurements, imaging markers of early disease or disease progression, artificial intelligence-enabled risk prediction, and imaging approaches that inform prevention, treatment monitoring, or longitudinal care before complications develop.

This category invites late-breaking research on imaging biomarkers that guide, monitor, and de-risk next generation immune, cellular, gene, and other advanced therapies. Submissions may address applications in oncology, neurology, inflammatory diseases, cardiovascular disease, rare genetic disorders, or other clinical areas. Topics may include imaging of target engagement, biodistribution, immune activation, treatment response, toxicity, adverse tissue effects, and long-term outcomes. Research involving molecular, metabolic, functional, microstructural, or AI-enabled quantitative imaging approaches is relevant, particularly when it demonstrates how imaging can support therapy selection, safety monitoring, response assessment, or translation of emerging therapies into clinical care.

This category invites late-breaking research on photon-counting CT applications that address clinical or technical challenges that are not currently feasible, or not adequately addressed, with conventional energy-integrating detector CT. Submissions should emphasize novel applications enabled by photon-counting CT, rather than incremental improvements in routine CT imaging. Relevant topics may include ultra-high-resolution vascular or musculoskeletal imaging, multi-energy and material-specific characterization, quantitative imaging applications such as iodine mapping, virtual non-contrast imaging, fat fraction or extracellular volume assessment, radiation or contrast dose reduction for otherwise limited applications, and portable, intraoperative, or point-of-care CT. Submissions are encouraged that demonstrate how photon-counting CT enables new diagnostic or interventional use cases, provides CT-based alternatives to applications currently performed with MRI, or substantially improves upon standard CT across organ systems.

Showcase your high-impact clinical trial on one of radiology’s most visible stages.

RSNA invites Late-Breaking Abstract submissions focused on high-impact clinical trials in radiology and medical imaging. Accepted abstracts will be featured in dedicated sessions at the RSNA 2026 Annual Meeting.

This category is intended for studies designed to generate practice-changing evidence for imaging tests, tools, interventions, technologies, or care pathways. Submissions should evaluate clinically meaningful outcomes with clear relevance for patients, clinicians, or health systems.

Eligible studies should meet the following criteria:

• Centered on medical imaging
• Designed to produce evidence with clear potential to influence clinical practice, guidelines, health system decision-making, or patient outcomes
• Conducted across multiple centers
• Preferably prospective in design
• Focused on clinically meaningful endpoints, such as morbidity or mortality, diagnostic yield, treatment selection, avoidance of unnecessary procedures, time to diagnosis or therapy, patient-reported outcomes, cost-effectiveness, workflow efficiency, health system impact, or equitable access to care
• Can be inclusive of novel imaging technologies or applications, when evaluated in a clinical trial framework
• Retrospective studies may be considered only if they provide evidence strong enough to influence clinical practice or guidelines. Meta-analyses and systematic reviews are not eligible.

Practice-changing trials that have been presented at another major clinical society meeting within the past year, or are scheduled for presentation before RSNA 2026, are eligible but must disclose the meeting name and date. Trials submitted as abstracts during the initial spring RSNA 2026 abstract call are not eligible.

Hypothesis-driven research that may be presented orally as a paper or as a digital presentation.

Education exhibits should be designed to teach or review topics related to medical imaging. They may be presented as digital presentations or standalone exhibits.

A $3,000 prize awarded to the top scientific paper in neuroradiology as selected by the Annual Meeting Program Planning Committee.

A $1,000 prize is awarded to an outstanding scientific presentation in each subspecialty presented by a resident, fellow, medical student or physics trainee. All applicants must be an RSNA Member-in-Training.

All eligible education exhibits are reviewed by the Education Exhibits Awards Committee appointed by the board of directors and awards are announced at the annual meeting.

All eligible scientific posters are reviewed and awards are announced at the annual meeting.

The requirement for financial disclosure from committee members, planners, reviewers, authors, and presenters is a mandatory element in maintaining ACCME accreditation for all organizations that provide continuing education (CE) activities. If an individual refuses to disclose, he/she will not be permitted to participate as a planner, committee member, reviewer, author, or presenter.

As an ACCME-accredited provider, the RSNA must ensure that education is fair and balanced and that any clinical content presented supports safe, effective patient care. The ACCME defines ineligible companies as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." 

Further, the provider must be able to show that individuals in a position to control the content of an education activity, including committee members, reviewers, planners, authors, and presenters, has disclosed all financial relationships with ineligible companies to the provider. Individuals in a position to control the content must disclose regardless of their view of the relevance of the relationship to the education. The provider must identify, mitigate, and disclose all identified financial relationships to an education activity being delivered to the learners.

If you have or have had within the previous 24 months such a relationship or affiliation, you must disclose this information. Likewise, disclosure that no relationship(s) exists is also required. The intent of this policy is not to prevent an individual with a financial relationship from participating; however, in accordance with ACCME standards, the RSNA has developed policies and procedures to manage identified financial relationships.